Logo

DriverMap Transcriptome Profiling in Drug Screening Applications

Lester Kobzik, MD
Thursday, November 29, 2018
Tweet
Transcript Embed
  • Email
  • Bookmark
  • <<
  • <
  • >
  • >>

Tweet
Facebook
  • Email

Chapters

  • Introduction
    • Phases of Drug Screening
      • Screening vs. A375 Melanoma: Leads identified---now what?
        • Drug Screen Transcriptional Signatures
          • DriverMap Technology Outline
            • DriverMap Assay: Key Applications
              • Experimental Protocol
                • Analysis Workflow
                  • Screening vs. A375 Melanoma: Leads identified---now what?
                    • Transcriptome profiling: A375 24h after drug treatment
                      • Drug Panel MOA Analysis using LINCS1000
                        • Transcriptome profiling: A375 24h after drug treatment
                          • Ingenuity IPA Causal Analysis of RAF Kinase Inhibition
                            • Drug Panel Cytotoxic Effects on A549 cells at 72h
                              • More Bioinformatic Analysis
                                • A375 Drug Response: Down-Regulated Pathways Common & Drug-Specific
                                  • RAF Inhibitors vs A375 (Dabrafenib, Sorafenib, Vemurafenib)
                                    • Summary
                                      • Acknowledgements

No transcript for this webinar

More InformationRequest info